Representative Lisa C. McClain (R-Michigan) recently bought shares of Merit Medical Systems, Inc. NASDAQ: MMSI. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Merit Medical Systems stock on July 22nd. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.
Representative Lisa C. McClain also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
- Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
- Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
- Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
- Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
- Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
- Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
- Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
- Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
- Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.
Merit Medical Systems Stock Down 0.0%
Shares of MMSI traded down $0.02 during midday trading on Friday, hitting $85.20. The stock had a trading volume of 145,475 shares, compared to its average volume of 656,120. The company has a 50 day simple moving average of $89.61 and a two-hundred day simple moving average of $96.03. Merit Medical Systems, Inc. has a twelve month low of $81.04 and a twelve month high of $111.45. The firm has a market cap of $5.05 billion, a price-to-earnings ratio of 43.31, a price-to-earnings-growth ratio of 2.82 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.09 and a quick ratio of 2.66.
Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.16. Merit Medical Systems had a return on equity of 15.07% and a net margin of 8.31%. The firm had revenue of $382.46 million for the quarter, compared to the consensus estimate of $372.47 million. During the same quarter last year, the business posted $0.92 EPS. The company's revenue for the quarter was up 13.2% on a year-over-year basis. On average, analysts anticipate that Merit Medical Systems, Inc. will post 3.37 EPS for the current year.
Hedge Funds Weigh In On Merit Medical Systems
Institutional investors have recently bought and sold shares of the business. Maseco LLP acquired a new position in Merit Medical Systems during the second quarter worth approximately $28,000. Opal Wealth Advisors LLC acquired a new position in Merit Medical Systems during the first quarter worth approximately $31,000. IFP Advisors Inc increased its position in Merit Medical Systems by 1,435.0% during the first quarter. IFP Advisors Inc now owns 307 shares of the medical instruments supplier's stock worth $32,000 after buying an additional 287 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Merit Medical Systems by 55.6% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 375 shares of the medical instruments supplier's stock worth $35,000 after buying an additional 134 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in Merit Medical Systems by 119.8% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 367 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 200 shares during the last quarter. Institutional investors and hedge funds own 99.66% of the company's stock.
Insider Activity
In other news, Director Lynne N. Ward sold 2,433 shares of the company's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $84.89, for a total value of $206,537.37. Following the transaction, the director owned 12,809 shares of the company's stock, valued at approximately $1,087,356.01. This represents a 15.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David Floyd sold 3,515 shares of the company's stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $94.16, for a total value of $330,972.40. Following the completion of the transaction, the director directly owned 4,880 shares in the company, valued at $459,500.80. The trade was a 41.87% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,779 shares of company stock valued at $6,327,983. 3.20% of the stock is owned by insiders.
Analyst Ratings Changes
MMSI has been the topic of several recent research reports. Canaccord Genuity Group set a $112.00 price target on Merit Medical Systems and gave the company a "buy" rating in a research note on Wednesday, May 21st. Raymond James Financial dropped their price target on Merit Medical Systems from $108.00 to $102.00 and set an "outperform" rating on the stock in a research note on Thursday, July 31st. Needham & Company LLC reaffirmed a "buy" rating and issued a $108.00 target price on shares of Merit Medical Systems in a research report on Friday, July 18th. Barrington Research reaffirmed an "outperform" rating and issued a $103.00 target price on shares of Merit Medical Systems in a research report on Thursday, July 31st. Finally, Piper Sandler lowered their target price on Merit Medical Systems from $110.00 to $105.00 and set an "overweight" rating on the stock in a research report on Thursday, July 31st. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $107.00.
Check Out Our Latest Stock Report on Merit Medical Systems
About Representative McClain
Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.
McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election.
Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.
Merit Medical Systems Company Profile
(
Get Free Report)
Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merit Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merit Medical Systems wasn't on the list.
While Merit Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here

We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report